Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Subscribe To Our Newsletter & Stay Updated
